FiercePharmaOriginal article
{"a":[{"_":"Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues","$":{"href":"/biotech/sanofis-new-ceo-looking-deeply-late-stage-pipeline-clinical-clearout-continues","hreflang":"en"}}]}
negativeitepekimabNegative
AI Analysis
Summary
Sanofi's new CEO Belén Garijo is reviewing the late-stage pipeline to address clinical setbacks, including discontinuing the Regeneron-partnered IL-33 candidate itepekimab as part of a broader clinical clearout strategy.
Outcome Details
Sanofi dumping IL-33 candidate itepekimab partnered with Regeneron as part of clinical clearout
Importance:6/10
Sentiment:
-0.70
pipeline_discontinuationclinical_setbackpartnershipstrategic_review
Read the original article
Published by FiercePharma on July 30, 2026 5:01 AM